Effects of NLS-133, a Potential Non-Hormonal "On-Demand" Male Contraceptive
NCT07393334
This study is recruiting at 1 US site in 1 state, according to its ClinicalTrials.gov record last updated .
Summary
NLS-133-CLIN001 is a Phase 2a study designed to assess the safety, tolerability, and effects of NLS-133 (combination of two FDA-approved agents) compared to an active control (FDA-approved pharmacologic agent) or placebo on semen volume and sperm count in 10 in healthy men. Participants will be randomized in a crossover design to receive a single dose of NLS-133, an active control or placebo either 90 or 180 minutes prior to collection of semen. Sperm parameters measured will be count, motility and morphology.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Male Contraception
- Semen Volume
- Sperm Motility
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 2
- Ages
- 18 to 55 years
- Sex
- Male
- Healthy volunteers
- Accepted
- Sponsor
- Next Life Sciences
- Last updated on ClinicalTrials.gov
- February 6, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Washington · 1
- Population Center for Research in Human Reproduction and Departments of Medicine, University of Washington · Seattle, WA
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.